Objective-Resolvin D1 (RvD1) limits neutrophil recruitment during acute inflammation and is derived from omega-3 docosahexaenoic acid to promote catabasis. The contribution of its specific receptors, the lipoxin A 4 /Annexin-A1 receptor formylpeptide receptor 2 (FPR2/ALX) and the orphan receptor G-protein-coupled receptor 32 (GPR32) are of considerable interest. Methods and Results-RvD1 reduced human polymorphonuclear leukocytes recruitment to endothelial cells under shear conditions as quantified using a flow chamber system. Receptor-specific antibodies blocked these anti-inflammatory actions of RvD1, with low (1 nmol/L) concentrations sensitive to GPR32 blockade, while the higher (10 nmol/L) concentration appeared FPR2/ALX-specific. Interestingly, polymorphonuclear leukocytes surface expression of FPR2/ ALX but not GPR32 increased following activation with pro-inflammatory stimuli, corresponding with secretory vesicle mobilization. Lipid mediator metabololipidomics carried out with 24-hour exudates revealed that RvD1 in vivo gave a significant reduction in the levels of a number of pro-inflammatory mediators including prostaglandins and leukotriene B 4 . These actions of RvD1 were abolished in fpr2 null mice. 
P olymorphonuclear leukocytes (PMN) are of paramount importance for host innate immune defense and are essential for ongoing health. However, excessive inflammation due to ungoverned leukocyte infiltration can become deleterious to the host and can progress to chronic disease. Indeed, uncontrolled, nonresolving inflammation is a hallmark of many prevalent pathologies including atherosclerosis and arthritis. 1 Contrary to initial belief, an acute inflammatory response does not merely subside because of dissipation of pro-inflammatory mediators. Accruing evidence now signifies that the resolving phase of inflammation is not a passive process, but actively switches-off via the biosynthesis of endogenous anti-inflammatory mediators. 2, 3 Omega-3 polyunsaturated fatty acids are known to bestow protective clinical effects in the cardiovascular system and inflammatory disorders including rheumatoid arthritis. 4, 5 Hence, the mechanisms by which omega-3 polyunsaturated fatty acids exert their biological effects are of ongoing interest. Lipidomics profiling of self-limited, inflammatory exudates led to the identification of unique omega-3-derived lipid mediators, designated resolvins and protectins, for their ability to actively accelerate inflammatory resolution. 6, 7 Resolvins exert potent anti-inflammatory and pro-resolving actions in experimental animal models and promote wound healing (reviewed in Ref. 8) . Furthermore, resolvins also help maintain vascular homeostasis; resolvin D2 (RvD2) stimulates vasoprotective prostacyclin and nitric oxide release from the vascular endothelium, 9 and EPA-derived RvE1 counterregulates platelet activation. 10 These anti-inflammatory and pro-resolving autacoids mediate their bioactions via specific G-protein-coupled receptors (GPCRs). Recently, 2 GPCRs for RvD1 (7S, 8R, 17S-trihydroxy-docosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid) 11 were identified and validated using a GPCR/β-arrestincoupled system, namely FPR2/ALX and an orphan receptor GPR32. 12 Initially characterized as a low-affinity N-formyl-MetLeu-Phe (fMLP) receptor and termed formyl-peptide receptor-like 1, FPR2/ALX has since been reclassified as a result of its high affinity for the endogenous ligand lipoxin A 4 . 13 Intriguingly, accumulating reports implicate FPR2/ALX as a multirecognition receptor that recognises a repertoire of protein/peptide agonists as well as high-affinity endogenous lipid ligands, which modulate the host immune response. 14, 15 Comparatively, little is currently known about the orphan human receptor GPR32. High-affinity ligands for both GPCRs include RvD1 and LXA 4 as well as the small molecule FPR2/ ALX agonist compound 43. 12 Expression levels of GPR32 are increased following monocyte exposure to GM-CSF or zymosan A for 24 to 48 hours, 12 although its relevance in pathophysiological settings needs to be determined. Moreover, the functional relevance of these 2 receptors in the biological actions of RvD1 on human PMN remains unclear.
Herein, we used an integrated approach with isolated human cells and a model of acute peritonitis, to provide direct evidence for GPCR-dependent actions of RvD1. On human PMN, low concentrations of RvD1 are sensitive to constitutive GPR32 expression and higher concentrations elicit FPR2/ ALX-mediated responses. We demonstrate unequivocally that the actions of RvD1 are dependent on receptor mechanisms, which could inform novel anti-inflammatory drug discovery programs.
Methods
Detailed information on protocols and ethics are available in the online-only Data Supplement.
In Vitro Flow Chamber Assay
Human umbilical vein endothelial cells were plated in µ-Slides VI 0.4 (Ibidi, Germany), and confluent monolayers stimulated with tumor necrosis factor (TNF)-α (10 ng/mL, 4 hours; R&D Systems). Human PMN were freshly isolated from healthy volunteers using dextran sedimentation followed by gradient centrifugation as described previously. PMN were preincubated with vehicle (0.1% EtOH) or RvD1 (0.01-100 nmol/L; Cayman Chemical) for 10 minutes at 37ºC, perfused over human umbilical vein endothelial cells at 1 dyne/cm 2 for 8 minutes, and then 6 random fields/treatment were recorded for 10 seconds each. The total number of interacting PMN was quantified as captured and further classified as rolling or adherent. In some experiments, PMN were preincubated for 10 minutes with anti-FPR2/ALX (10 μg/mL; FN-1D6-A1, Genovac), anti-GPR32 (10 µg/mL; GTX71225, GeneTex), or isotype controls, mouse IgG1 (BD Biosciences) or rabbit IgG (10 µg/mL; GeneTex) prior to incubation with vehicle or RvD1 (1-100 nmol/L, 10 minutes; Cayman Chemical).
Flow Cytometric Analysis
To assess PMN degranulation, cells were stimulated with vehicle (0.1% EtOH), TNF-α (10 ng/mL, R&D Systems), platelet-activating factor (C16 form: C 26 H 54 NO 7 P; 1 nmol/L, Sigma), interleukin-8 (IL-8; 10 nmol/L, R&D Systems), fMLP (1 µmol/L, Sigma), or fMLP plus cytochalasin B (5 µmol/L, Sigma) for 15 minutes at 37ºC. Surface expression of FPR2/ALX (10 µg/mL) and GPR32 (10 µg/ mL) were determined following incubation with fluorescein isothiocyanate-conjugated anti-mouse IgG (5 µg/mL; STAR9B, Serotec) and Alexa-488 goat anti-rabbit IgG (10 µg/mL; Invitrogen), respectively. Granule markers CD35 (20 µg/mL; E11, Serotec), CD63 (20 µg/mL; MEM-259, Serotec), and CD66b (1 µg/mL; G10F5, BioLegend) were determined by flow cytometry. In addition, CD62L (1 µg/mL; DREG56, eBioscience) and CD11b (1 µg/mL, ICRF44, eBioscience) were also monitored. In a separate set of experiments, surface expression of FPR2/ALX and GPR32 were determined on human PMN treated with or without TNF-α (10 ng/mL; 5 minutes, 37°C), then vehicle (0.1% EtOH) or RvD1 0.01 to 100 nmol/L for 10 minutes at 37°C. In all cases, antibodies or relevant isotype controls were incubated at 4°C prior to flow cytometric analysis using a FACSCalibur flow cytometer using CellQuest II Software (Becton Dickinson).
Murine Peritonitis
Peritonitis was assessed in fpr2 null and littermate controls (male mice, 6-8 weeks) generated and bred in house as detailed previously. 16 Vehicle (0.1% EtOH) or RvD1 (0.1-10 ng/mouse; Cayman Chemical) was administered intravenously followed by intraperitoneal administration of zymosan A (0.2 mg; Sigma-Aldrich). Peritoneal lavages were collected after 4 or 24 hours, and leukocyte infiltration was assessed by light microscopy, followed by differential analysis using anti-Ly6G (clone 1A8, BD Pharmingen) and anti-F4/80 (clone BM8, BD Pharmingen) staining and flow cytometry analysis.
Sample Extraction and Mediator Lipidomics
All samples for liquid chromatography-tandem mass spectrometry analysis were extracted with solid phase extraction columns as outlined in Ref. 17 . Prior to sample extraction, 500 pg of deuterium-labeled internal standards d 8 5S-hydroxyeicosatetraenoic acid (HETE), d 4 -leukotriene (LT)B 4 , d 5 -lipoxin (LX)A 4 , and d 4 -prostaglandin (PG)E 2 were added to facilitate the quantification of sample recovery. Extracted samples were analyzed by a liquid chromatography-ultraviolet-tandem mass spectrometry/MS system, QTrap 5500 (ABSiex) equipped with an Agilent HP1100 binary pump and diode-array detector. An Agilent Eclipse Plus C18 column (50 mm × 4.6 mm × 1.8 μm) was used with a gradient of methanol/ water/acetic acid of 60:40:0.01 (v/v/v) to 100:0:0.01 at 0.4-mL/min flow rate. Identification was conducted using previously published criteria using a minimum of 6 diagnostic ions. 17 Quantification was carried out based on the peak area of the multiple reaction monitoring transition and the linear calibration curve for each compound.
Zymosan Phagocytosis
Macrophages were harvested from fpr2 null and wild-type (WT) mice 4 days after intraperitoneal administration of 1 mL, 2% P-100 Bio-Gel in sterile PBS (Bio-Rad). Peritoneal lavages were filtered through 70 μm cell strainers (BD Biosciences), and cells seeded in 96-well plates (1×10 5 /well). Nonadherent cells were removed, and macrophages were incubated with RvD1 (0.001-100 nmol/L; Cayman Chemical) for 30 minutes, 37ºC in Roswell Park Memorial Institute media containing 0.1% fetal calf serum prior to the addition of fluorescein isothiocyanate-labeled zymosan at a 1:20 ratio (2×10 6 /well; Invitrogen). After 20 minutes, cells were washed 3 times and fluorescence was determined using a plate reader (NOVOstar, BMG Labtech, Germany).
Statistics
Data are mean±SEM. Multiple group comparisons were made using 1-way ANOVA followed by Dunnett's or Bonferroni's post hoc analysis. P<0.05 was considered significant.
Results

Resolvin D1 Attenuates PMN Recruitment Under Flow
We first tested RvD1 actions on human PMN recruitment under shear conditions, at a physiological flow rate relevant to leukocyte recruitment in an inflamed postcapillary venule.
18 RvD1 drastically reduced PMN-endothelial interactions, significantly blunting initial PMN capture, rolling, and firm adhesion to TNF-α-stimulated endothelium in a concentration-dependent manner ( Figure 1A-1C ). We initially selected 1 and 10 nmol/L concentrations, giving near-maximal inhibition, to identify which receptors were mediating the effect of RvD1.
PMN were preincubated with blocking antibodies for either FPR2/ALX or GPR32 prior to treatment with RvD1, and the extent of PMN accumulation was then assessed. At the low concentration of 1 nmol/L, RvD1 led to a significant attenuation in PMN capture, rolling, and adhesion, which was reversed when cells were preincubated with anti-GPR32 ( Figure 2A) . Intriguingly, the neutralizing anti-FPR2/ALX antibody did not annul the actions of 1 nmol/L RvD1, and in fact led to a further decrease in the number of rolling cells. Simultaneous pretreatment with both antibodies led to a similar level of recruitment seen with vehicle control-treated PMN, highlighting that the actions of RvD1 were abrogated when both GPCRs were neutralized. Notably, preincubation of PMN with isotype control antibodies did not alter the anti-inflammatory effects of RvD1 (data not shown).
Using a higher concentration of 10 nmol/L RvD1, a converse finding was observed, with the inhibitory actions now sensitive to FPR2/ALX blockade ( Figure 2B ). In addition, preincubation with anti-GPR32 caused a further decrease in PMN-endothelial interactions by RvD1. Congruently, coincubation with both blocking antibodies depleted the actions of 10 nmol/L RvD1, similar to low 1 nmol/L concentrations, emphasizing GPCR dependency for RvD1 actions on human PMN. We next tested an intermediate concentration of 3 nmol/L RvD1 that seemed to act via both GPCRs, because blocking either receptor alone did not revert its effects whereas cell coincubation with both antibodies was required to abrogate the actions of RvD1 ( Figure I in the online-only Data Supplement). Notably, preincubation of PMN with anti-FPR2/ALX or GPR32 alone did not alter PMN-endothelial interactions, suggesting that these antibodies do not exert agonist actions ( Figure I in the online-only Data Supplement).
Further support of receptor engagement was attained monitoring GPR32 and FPR2/ALX expression following incubation with the agonist RvD1 (0.01-100 nmol/L). Internalization of GPR32 was observed following exposure to low concentrations of RvD1 (0.1-1 nmol/L), whereas FPR2/ALX was maximally internalized when PMN were first activated with a proinflammatory stimulus ( Figure II in the online-only Data Supplement).
Proinflammatory Stimuli Mobilize FPR2/ALX to the PMN Surface
Given that PMN respond to physiological concentrations of RvD1 via 2 distinct receptors, we next addressed whether these receptors could be differentially modulated following cell activation. Stimulation of PMN with TNF-α, platelet-activating factor, and IL-8 caused a significant increment in FPR2/ALX expression ( Figure 3A) , whereas surface levels of GPR32 were not altered ( Figure 3B ). The status of PMN activation was monitored by CD11b upregulation ( Figure 3C ) and CD62L shedding ( Figure 3D ).
PMN store a vast selection of functionally important molecules in cytoplasmic granules and vesicles, which can be promptly mobilized on cell activation, allowing fast PMN responses. 19 To decipher whether FPR2/ALX expression correlates with PMN degranulation, cell surface expression of granule markers was also quantified. Liberation of secretory vesicles was monitored using PE-conjugated anti-CD35; these vesicles have the highest propensity for mobilization, and surface levels were elevated on PMN stimulation with platelet-activating factor, IL-8, and TNF-α, correlating with enhanced FPR2/ALX mobilization. Stimulation with high concentrations of fMLP caused secretory vesicle release but only marginally increased FPR2/ALX levels. Following PMN incubation with fMLP and cytochalasin B, we did not observe a significant elevation in cell surface CD35 levels most likely attributable to a complete release of these vesicles from the PMN cell surface ( Figure 3E) . Specific granules contain a large number of essential adhesion molecules including the heterodimer CD11b/CD18, and indeed CD11b expression ( Figure 3C ) mirrored mobilization of the specific granule marker CD66b ( Figure 3F) . Although a prominent increase in CD66b was observed with fMLP alone or in combination with cytochalasin B, FPR2/ ALX expression was not analogous, suggesting that secretory vesicles store the major reserve of this receptor. Primary azurophil granule release was initiated by stimulating PMN with fMLP along with cytochalasin B and monitored using fluorescein isothiocyanate-conjugated anti-CD63 ( Figure   3G ). Surface levels of RvD1 receptors were not increased, indicating that these GPCRs are not localized within primary granules. Notably, following exposure of PMN to RvD1 (0.01-100 nmol/L), no change in CD11b or CD62L expression was observed nor did RvD1 stimulate the release of granule-associated markers (data not shown). In contrast to the rapid modulation of FPR2/ALX observed in PMN, stimulating human umbilical vein endothelial cell along our experimental conditions (with or without TNF-α; 4 hours) did not alter FPR2/ALX or GPR32 expression ( Figure III in the online-only Data Supplement).
RvD1 Counter-Regulates Leukocyte Recruitment via fpr2 In Vivo
Intraperitoneal injection of zymosan provoked marked accumulation of leukocytes at 4 hours, with an average of 7.5 × 10 6 leukocytes per mouse exudate, which was similar in both genotypes. Administration of RvD1 (at 1 ng/mouse) significantly reduced total leukocytes and Ly6G + neutrophil infiltration in WT mice ( Figure 4B and 4D ). These anti-inflammatory actions of RvD1 were abolished in the absence of fpr2, Lipid mediator metabololipidomics were performed with exudates obtained 24 hours after zymosan as cell-free supernatants to elucidate the potential mechanism(s) underlying RvD1 actions in WT mice. We identified the following eicosanoids; lipoxin (LX) B 4 , 5,15-diHETE, and LTB 4 from the lipoxygensae pathway and PGE 2 , PGD 2 , PGF 2 , and thromboxane B 2 from cyclooxygenase pathways ( Figure 5A ). Identification was conducted using published criteria 20 (eg, LXB 4 and 5,15-diHETE; Figure 5B ). Using multiple reaction monitoring, we quantified the individual mediator amounts and found that RvD1 activated lipoxin biosynthesis stimulating the production of the anti-inflammatory mediator LXB 4 21 and LX-pathway marker 5,15-diHETE ( Figure 5C and 5D ). RvD1 also stimulated the biosynthesis of the cyclooxygenasederived PGE 2 ( Figure 5E ) while downregulating production of the proinflammatory lipoxygenase derived LTB 4 ( Figure  5F ). We also found that RvD1 reduced the biosynthesis of the cyclooxygenase-derived prostanoids PGD 2 , PGF 2 (≈25-50%; Figure 5G and 5H) and thromboxane B 2 ( Figure 5I ).
This exquisite lipid mediator regulation by RvD1 is lost in the fpr2 null mice, where a significant reduction in the baseline levels for some of the lipoxygenase products such as LXB 4 and LTB 4 was obtained ( Figure 5C and 5F).
RvD1 also exhibits proresolving actions, enhancing the clearance of microbial particles and apoptotic cells to promote catabasis. 12, 22 Herein, we investigated whether the proresolving actions of RvD1 on murine macrophage phagocytosis was mediated via FPR2/ALX. To test this, we harvested Biogel-elicited macrophages from either WT or fpr2 null mice, and preincubated them with vehicle or RvD1 (0.01-100 nmol/L) for 30 minutes prior to the addition of fluorescently labeled zymosan. Vehicle median fluorescence intensity values for macrophage zymosan phagocytosis were 1885 ± 380 WT versus 1840 ± 396 fpr2 −/− , thus no difference was observed between baseline phagocytosis levels of macrophages isolated from either WT or fpr2 −/− mice after 20 minutes of phagocytosis. As predicted, RvD1 significantly enhanced zymosan phagocytosis in WT macrophages ( Figure 6A ), but failed to increment phagocytosis in fpr2 null macrophages ( Figure 6B ). 
Discussion
PMN recruitment to inflammatory sites comprises a cascade of events including capture, rolling and adhesion to the vascular endothelium, and diapedesis into the underlying tissue. 23 Although these processes are well characterized, the counterregulation of PMN recruitment by endogenous anti-inflammatory and proresolving mediators is less renowned. Indeed, control of PMN influx is necessary to prevent unwanted tissue damage, thus the timely resolution of an inflammatory reaction is pertinent to maintain tissue homeostasis.
In the present study, we demonstrate that the anti-inflammatory and proresolving lipid mediator, RvD1 limits human PMN recruitment under shear conditions in a mechanism dependent on its receptors. Recently, 2 independent GPCRs were identified that RvD1 specifically binds on human leukocytes, namely FPR2/ALX and GPR32.
12 As yet, a thorough investigation into which of these receptors RvD1 signals to limit human PMN recruitment remained elusive. An apparent dichotomy in receptor involvement was evident depending on the amount of RvD1, with low concentrations appearing to be GPR32 specific and increased concentrations eliciting FPR2/ALX-dependent responses (illustrated in Figure IV in the online-only Data Supplement). Accordingly, incubation of unstimulated PMN with low concentrations of RvD1 (0.1-10 nmol/L) led to internalization of GPR32 from the plasma membrane, whereas FPR2/ ALX was maximally internalized on TNF-α-activated PMN using 10-100 nmol/L RvD1, implicating receptor engagement. Recently, FPR2/ALX internalization was reported as a prerequisite for the prophagocytic actions of LXA 4 and Annexin-A1-derived peptides. 24 The anti-inflammatory actions of RvD1 on human PMN are in concordance with recent results, whereby RvD1 blocks actin polymerization and CD11b upregulation induced by the proinflammatory lipid mediator LTB 4 , 12 decreases transendothelial migration under static conditions, 11 and reduces chemotaxis toward an IL-8 gradient. 25 An intriguing observation was noted when PMN were preincubated with anti-GPR32 prior to incubation with 10 nmol/L RvD1, which resulted in a further decrease in PMNendothelial interactions. We postulate that in inflammatory settings, when RvD1 concentrations are raised to orchestrate catabasis, 26 RvD1 signals via FPR2/ALX, which is upregulated following PMN activation. Recent studies have examined FPR2/ALX promoter activity and found that LXA 4 enhances the transcription of this receptor, in a proresolving feedback circuit. 27 It is noteworthy that increased levels of proresolving mediators and FPR2/ALX are detected in human pathologies including rheumatoid arthritis 28, 29 and acute poststreptococcal glomerulonephritis, 30 suggesting that protective mediators and their receptors are both operative within inflammatory settings to aid resolution. Of interest, increasing evidence suggests that several pathologies perpetuate because of the failure of inflammatory resolution, including atherosclerosis 22 and periodontitis. 31 Thus, persistent/chronic inflammation may not merely be because of excessive production of proinflammatory mediators and also attributed to a defect in endogenous anti-inflammatory and proresolving pathways. Recently, lipid mediator metabolomics has proved a useful measure of resolution outcomes, with protective mediators associated with early rather than late responders following postoperative abdominal aortic aneurysm repair. 32 PMN are equipped with multiple types of intracellular granules allowing efficient innate effector functions. On stimulation, PMN mobilize vesicles and granules to the plasma membrane, which contain receptors, cell adhesion molecules, and proteases to promptly facilitate PMN adhesion, diapedesis, and killing of bacteria among other roles. Although these processes are necessary for host defense, granule release is tightly controlled as their contents can cause extensive tissuedamage. There are 4 main types of PMN vesicles/granules that are categorised based on their content and propensity for liberation. In sequential order, secretory vesicles are first mobilized and provide adhesion molecules for PMN recruitment and transendothelial migration, while gelatinase granules contain metalloproteases required for matrix degradation and hence PMN migration to the inflammatory milieu. Specific granules comprise antimicrobial peptides, whereas the final type to be rallied, the azurophil granules permit proteolytic enzyme release into the phagosome to aid bacterial killing. 19 Using flow cytometric analysis, we investigated the surface expression of FPR2/ALX and GPR32 following stimulation with an array of proinflammatory mediators and in parallel monitored PMN granule mobilization. FPR2/ALX surface levels were increased with proinflammatory stimuli, which coincided with a similar increase in CD35 expression, signifying secretory vesicle release. Notably, FPR2/ALX surface expression is elevated on human blister exudate PMN, 33 further supporting the notion that this receptor can be rapidly mobilized on the cell surface as part of a counter-regulatory mechanism. Surface expression of CD66b was also enhanced following PMN activation; therefore, it is also possible that FPR2/ALX is harbored within the specific granules.
Collectively, these results demonstrate that FPR2/ALX surface expression is rapidly increased on activation with stimuli that PMN sense during an inflammatory response to help counter-regulate exuberant PMN recruitment. However, GPR32 in human PMN is constitutively and stably expressed and can respond to low concentrations of endogenous antiinflammatory mediators with the aim of conveying normal physiological functions.
In murine physiology, fpr2 represents the human orthologue for FPR2/ALX, 14 whereas there is no known murine counterpart of human GPR32. 34 Thus, we investigated the GPCR dependency of RvD1 in an acute inflammatory model by using fpr2-deficient mice. RvD1 significantly reduced peritoneal PMN infiltration in WT mice; of interest, the actions of RvD1 were abolished in the fpr2-deficient mice, signifying the essential role of the RvD1-FPR2/ALX axis in the mouse. No differences in cell recruitment between WT and fpr2-deficient mice were observed at this time-point. A finding that was inline with those published, with no differences in cell recruitment seen in the acute inflammatory models of peritonitis and IL-1β air pouch between genotypes, whereas enhanced responses emerged in fpr2 null mice when tested in the carrageenan paw edema and inflammatory arthritis models. 16 Treatment with RvD1 modulated peritoneal lipid mediators, enhancing levels of anti-inflammatory and proresolving lipid mediators including LXB 4 and the LX-pathway marker 5,15-diHETE, while decreasing proinflammatory lipid mediators including thromboxane B 2 , PGF 2 , and LTB 4 in WT mice. Importantly, PMN-directed regulatory actions of RvD1 were not observed in fpr2 null mice demonstrating the pivotal function of this receptor in mediating these important and complex responses. RvD1 treatment also enhanced the production of PGE 2 in WT mice, which is known to promote vascular responses and lipid mediator class switching that enhances the resolution of acute inflammation. 35 Because RvD1 also stimulated endogenous LXB 4 ( Figure 5C ), we cannot rule out that the anti-inflammatory actions of RvD1 in vivo were mediated, at least in part, by LXB 4 which possesses potent anti-inflammatory actions. 21 Relevantly, RvD1 was recently shown to modulate a repertoire of mediators and pathways via miRNAs, including the enzyme 5-lipoxygenase. 36 Thus, perhaps in the absence of the RvD1 receptor, baseline levels of 5-lipoxygenase products including LXB 4 and LTB 4 are differential in fpr2 null mice. The proresolving phagocytic actions of RvD1 were also abrogated in fpr2 null macrophages, further reenforcing the crucial role of FPR2/ALX in conveying proresolving effects of RvD1 in murine tissue. Corroborative results were obtained for LXA 4 , which enhanced phagocytosis by bone marrow-derived macrophages from WT but not fpr2 null cells, implicating FPR2/ALX as a multirecognition yet proresolving receptor. 24 In the absence of exogenous agonists, transgenic mice overexpressing human FPR2/ALX display reduced PMN infiltration in zymosan peritonitis, 37 and mice lacking the murine homologue receptor display an exacerbated response to ischemia-reperfusion injury and arthritogenic serum, 16 further supporting a protective role of this receptor in inflammation. Indeed, human monocyte-derived macrophages treated with RvD1 display enhanced zymosan phagocytosis, a response further enhanced when these cells are transfected with either FPR2/ALX or GPR32. 12 Our findings reinforce the central role of FPR2/ALX to transmit regulatory circuits of interest in controlling vascular inflammation that highlight a functional role for GPR32 in mediating homeostasis. Importantly, we report the receptormediated actions of RvD1 with potent regulation of human PMN recruitment and regulation of lipid mediator biosynthesis (without completely blocking PMN-endothelial interactions) as well as enhanced clearance of zymosan. This is inline with other specialized proresolving lipid mediators that enhance antimicrobial actions of phagocytes without causing immunosuppression. 9, 38, 39 Hence these results establish the RvD1-GPCR interactions in vivo that govern proresolving mechanisms. Further study of these can provide a new appreciation of the underlying mechanisms in inflammationassociated diseases and may impact on drug discovery programs aiming at developing novel therapeutics for vascular pathologies.
